SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees

Abaloparatide (ABL) is a novel, selective activator of the PTH1 receptor signaling pathway. In the 18-month Phase 3 ACTIVE study in women with postmenopausal osteoporosis (NCT01343004), ABL significantly increased bone mineral density (BMD), and decreased the risk of vertebral (VF), nonvertebral (NV...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Endocr Soc
Hoofdauteurs: Saag, Kenneth, Williams, Setareh, Wang, Yamei, Weiss, Richard, Cauley, Jane
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Endocrine Society 2019
Onderwerpen:
Bone and Mineral Metabolism
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552091/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-519
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items